Nuvectis Pharma (NASDAQ:NVCT) Stock Dropped to “Strong Sell” by Zacks Research

Zacks Research downgraded shares of Nuvectis Pharma (NASDAQ:NVCT) from a hold rating to a strong sell rating in a report published on Thursday morning,Zacks reports.

Other equities research analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $39.00 target price on shares of Nuvectis Pharma in a research report on Thursday, September 24th. Lucid Cap Mkts upgraded shares of Nuvectis Pharma to a “strong-buy” rating in a research report on Tuesday, September 1st. Wall Street Zen lowered Nuvectis Pharma from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings raised shares of Nuvectis Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 21st. Finally, Loop Capital set a $40.00 target price on Nuvectis Pharma in a research note on Tuesday, September 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Nuvectis Pharma has a consensus rating of “Moderate Buy” and an average price target of $36.25.

Nuvectis Pharma Stock Up 17.7%

NASDAQ NVCT traded up $3.15 during trading on Thursday, hitting $20.91. 257,686 shares of the stock traded hands, compared to its average volume of 171,396. The company has a market capitalization of $682.50 million, a P/E ratio of -11.06 and a beta of -0.21. Nuvectis Pharma has a 12-month low of $5.55 and a 12-month high of $29.27. The firm has a 50-day simple moving average of $20.89 and a 200-day simple moving average of $14.88.

Nuvectis Pharma (NASDAQ:NVCT) last announced its earnings results on Wednesday, November 4th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.78). As a group, research analysts predict that Nuvectis Pharma will post -1.30 EPS for the current fiscal year.

Institutional Investors Weigh In On Nuvectis Pharma

Several institutional investors have recently modified their holdings of NVCT. Legal & General Group Plc purchased a new position in shares of Nuvectis Pharma during the second quarter valued at approximately $31,000. Bank of America Corp DE acquired a new stake in shares of Nuvectis Pharma in the second quarter valued at about $218,000. Avalon Trust Co purchased a new stake in shares of Nuvectis Pharma during the second quarter valued at approximately $257,000. Deutsche Bank AG acquired a new position in Nuvectis Pharma in the 2nd quarter worth $310,000. Finally, Bank of New York Mellon Corp purchased a new position in Nuvectis Pharma in the second quarter valued at about $676,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Key Headlines Impacting Nuvectis Pharma

Here are the key news stories impacting Nuvectis Pharma this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $39 price target, well above the stock’s quoted $20.91 price. Nuvectis Pharma analyst coverage
• Negative Sentiment: Zacks Research downgraded NVCT from “hold” to “strong sell,” a bearish change in analyst sentiment that could weigh on shares. TickerReport article
• Negative Sentiment: HC Wainwright lowered its expected earnings per share for Q4 2026 and FY2026–FY2028, signaling larger projected losses. Its FY2026 estimate, for example, moved from a loss of $1.02 to $1.91 per share; the FY2027 and FY2028 loss forecasts also increased. Nuvectis Pharma analyst coverage

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, with an emphasis on cancers that have limited therapeutic options. The company is headquartered in Fort Lee, New Jersey, and its common stock trades on the Nasdaq Capital Market under the symbol NVCT.

Nuvectis Pharma’s lead product candidate is NXP800, an orally administered small-molecule inhibitor of heat shock protein 90 (HSP90). The company is evaluating NXP800 in clinical studies for certain advanced solid tumors, including platinum-resistant ovarian cancer and cholangiocarcinoma.